Page 482 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer

Appendix Table C4.1. Descriptive characteristics of the randomized controlled trials and comparative cohort studies considered
relevant to KQ4 (continued)
Author, Year Study name Comparison Study Sample Inclusion criteria Population description: Quality
[Pubmed ID] /Database duration size (total) Age Comments
PSA (ng/mL)
Study design Tumor grade
Stage
Penson 235 CaPSURE WW vs. 1 yr 235 Patients enrolled in CaPSURE Mean age: 69.0 C
2001 active at the time of diagnosis, with
11248628 treatments T1c or T2 tumors, and complete PSA: <10, 59%; 10-20, 27%;
RP resource date during followup >20, 12%; unknown, 2%
Retrospective monotherapy,
cohort RP + Gleason score: 2-4, 7%; 5-6,
neoadjuvant 58%; 7-10, 32%; unknown, 3%
hormone
therapy; RT Stage: T1c, 25%; T2a/b, 44%;
monotherapy, T2c, 31%
RT +
neoadjuvant
hormonal
therapy;
medical
pADT,
orchiectomy,
medical pADT
followed by
orchiectomy]

C-159